Literature DB >> 7452488

The beneficial effects of oral ibuprofen on coronary artery thrombosis and myocardial ischemia in the conscious dog.

J L Romson, L R Bush, D W Haack, B R Lucchesi.   

Abstract

The nonsteroidal anti-inflammatory agent, ibuprofen, was evaluated for its in vivo antithrombotic effects in conscious canines by inducing left circumflex (LCX) coronary artery thrombosis with low amperage stimulation (50 microA for 24 hr) of the intimal surface of the vessel. Oral administration of ibuprofen (75 or 175 mg/kg in divided doses) prevented occlusive LCX thrombosis. Compared to controls, oral ibuprofen treatment resulted in a significant reduction in developed LCX thrombus mass (20 +/0 2 mg vs. 10 +/- 0.3 mg wet weight, P < .005) and left ventricular infarct mass (24 +/- 4% vs. 1 +/- 0.5%, P < .005). Scanning electron microscopy of the luminal surface of the LCX revealed minimal platelet adherence on the damaged intima in ibuprofen-treated animals. In a separate series of experiments, intervention with oral ibuprofen (12.5 mg/kg every 4 hr) reduced the extent of myocardial ischemic injury resulting from 60 min of complete LCX occlusion followed by reperfusion, whether assessed on the basis of the total left ventricular mass (18 +/- 2% vs. 9 +/- 3%, P < .02) or the area at risk (50 +/- 7% vs. 20 +/- 3%, P < .02). These results suggest that ibuprofen possesses significant antithrombotic and myocardial protective properties which may be valuable in the prevention of coronary artery thrombosis and ischemic heart disease.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7452488

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

Review 1.  Ibuprofen in acute-care therapy.

Authors:  W B Rockwell; H P Ehrlich
Journal:  Ann Surg       Date:  1990-01       Impact factor: 12.969

2.  Cyclocreatine inhibits the production of neutrophil chemotactic factors from isolated hearts.

Authors:  S A Elgebaly; M E Allam; E F Rossomando; G A Cordis; F Forouhar; A Farghaly; D L Kreutzer
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

3.  Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.

Authors:  D J Fitzgerald; J Doran; E Jackson; G A FitzGerald
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

4.  Comparison of the effects of molsidomine, nitroglycerin and isosorbide dinitrate on experimentally induced coronary artery thrombosis in the dog.

Authors:  P A Martorana; B Kettenbach; H Göbel; R E Nitz
Journal:  Basic Res Cardiol       Date:  1984 Sep-Oct       Impact factor: 17.165

5.  Prostacyclin prevents ventricular fibrillation in a canine model of sudden cardiac death.

Authors:  V B Fiedler; M Mardin
Journal:  Basic Res Cardiol       Date:  1986 Jan-Feb       Impact factor: 17.165

6.  The effects of oral nafazatrom (= BAY g 6575) on canine coronary artery thrombosis and myocardial ischemia.

Authors:  V B Fiedler
Journal:  Basic Res Cardiol       Date:  1983 May-Jun       Impact factor: 17.165

7.  Thrombolytic effects of intracoronary streptokinase on canine coronary artery thrombosis.

Authors:  V B Fiedler
Journal:  Basic Res Cardiol       Date:  1984 Jan-Feb       Impact factor: 17.165

8.  The effects of nafazatrom in an acute occlusion-reperfusion model of canine myocardial injury.

Authors:  V B Fiedler; M Mardin; E Perzborn; R Grützmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

9.  Platelet depletion in experimental myocardial infarction.

Authors:  S R Jolly; W A Schumacher; S L Kunkel; G D Abrams; J Liddicoat; B R Lucchesi
Journal:  Basic Res Cardiol       Date:  1985 May-Jun       Impact factor: 17.165

10.  Ibuprofen abolishes the increase in leucocyte chemiluminescence observed during ischemic myocardial failure, but fails to improve hemodynamic function.

Authors:  K Ytrehus; A G Semb; E S Myhre
Journal:  Basic Res Cardiol       Date:  1992 Jul-Aug       Impact factor: 17.165

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.